Tandem high‐dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high‐risk medulloblastoma or supratentorial primitive neuro‐ectodermic tumors

Pediatric Blood and Cancer - Tập 61 Số 8 - Trang 1398-1402 - 2014
Christelle Dufour1, Virginie Kieffer1,2, Pascale Varlet3, Marie Anne Raquin1, F. Dhermain4, Stéphanie Puget5, Dominique Valteau‐Couanet1, Jacques Grill1
1Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France
2Physical Medicine and Rehabilitation Department for Children With Acquired Neurological Injuries Hôpital National de Saint Maurice Saint‐Maurice France
3Department of Neuropathology, Sainte Anne Hospital, Paris, France
4Department of Radiation Oncology, Gustave Roussy, Villejuif, France
5Department of Neurosurgery Necker‐Enfants Malades Hospital Paris France

Tóm tắt

BackgroundTo assess the feasibility and effectiveness of high‐dose chemotherapy (HDC) with stem cell support followed by conventional craniospinal radiotherapy (RT) as treatment for children older than 5 years of age with newly diagnosed high‐risk medulloblastoma (MB) or supratentorial PNET (sPNET).ProcedureBetween May 2001 and April 2010, 24 children older than 5 years of age (MB = 21; sPNET = 3), fulfilling inclusion criteria at diagnosis, were treated at Gustave Roussy. After conventional chemotherapy, they received two courses of high‐dose thiotepa (600 mg/m2) followed by craniospinal RT.ResultsThe median follow‐up was 4.4 years (range, 0.8–11.3 years). For children with metastatic MB, the 5‐year event‐free survival (EFS) and overall survival (OS) were 72% and 83%, respectively. The toxicity was manageable. No toxic death occurred. At the most recent evaluation, among the 24 children who had at least one Full Scale Intellectual Quotient (FSIQ) examination at a median follow‐up of 3.79 years after diagnosis, the mean estimated FSIQ was 82 (range, 56–114).ConclusionsIn children with metastatic MB, tandem HDCT with ASCT followed by conventional craniospinal RT proved its feasibility without jeopardizing survival. Pediatr Blood Cancer 2014; 61:1398–1402. © 2014 Wiley Periodicals, Inc.

Từ khóa


Tài liệu tham khảo

10.1016/S1470-2045(04)01424-X

10.1002/1097-0142(19880515)61:10<1992::AID-CNCR2820611011>3.0.CO;2-J

10.3171/jns.1994.81.5.0690

10.1200/JCO.2001.19.10.2696

10.1016/j.ejca.2006.02.026

10.1200/JCO.1999.17.3.832

10.1200/JCO.2004.12.126

10.1016/S1470-2045(06)70867-1

10.1016/S1470-2045(06)70872-5

10.1007/s00401-007-0243-4

Grill J, 2005, Preoperative chemotherapy in children with high‐risk medulloblastomas: A feasibility study, J Neurosurg, 103, 312

RiccardiR CefaloG RuggieroA et al. editors.Antitumor activity of temozolomide in medulloblastoma—PNET. 12th international symposium on pediatric neuro‐oncology; 2006; Nara Japan.

10.1148/93.6.1351

10.1002/1097-0142(19851001)56:7 <1824::AID-CNCR2820561321>3.0.CO;2-H

10.1093/neuonc/nos304

10.1016/S0360-3016(96)00450-6

10.1016/S0360-3016(98)00413-1

10.1200/JCO.2008.18.4176

10.1200/JCO.2011.40.2792

10.1016/S0360-3016(99)00177-7

10.1200/JCO.1998.16.5.1723

10.1016/S0360-3016(00)01351-1

10.1002/ana.10029

10.1002/pbc.20329

10.1200/JCO.2001.19.8.2302

Thông tin
Thông tin xuất bản

Pediatric Blood and Cancer

Tập 61 Số 8

1398-1402

Thông tin tác giả